Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ocular Therapeutix, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:05.140 Good morning and welcome to the Ocular Therapeutics second quarter 2025 earnings 00:00:05.140 -- 00:00:10.100 conference call. At this time all participants are in a listen only mode. 00:00:10.100 -- 00:00:14.000 After the prepared remarks we will conduct a question and answer session. 00:00:14.000 -- 00:00:19.040 To ask a question please press star 1. As a reminder this conference call is 00:00:19.040 -- 00:00:24.120 being recorded and will be available for replay on the investor relations section of 00:00:24.120 -- 00:00:29.000 the Ocular Therapeutics website. I would now like to turn the call over to Ocular's Vice 00:00:29.000 -- 00:00:32.460 President of Investor Relations, Bill Slattery Jr. 00:00:32.460 -- 00:00:34.260 Please go ahead Mr. 00:00:34.260 -- 00:00:39.580 Slattery. Good morning everyone and thank you for joining us today. 00:00:39.580 -- 00:00:44.460 Earlier this morning we issued a press release and filed our quarterly report on form 00:00:44.460 -- 00:00:49.780 10Q, outlining our financial results and business updates for the second quarter 00:00:49.780 -- 00:00:54.840 of 2025, along with several updates to our registration program 00:00:54.840 -- 00:00:58.220 for ex-Paxley and wet AMD. 00:00:58.700 -- 00:01:02.660 Ocular's Executive Chairman, President and CEO, Dr. 00:01:02.660 -- 00:01:07.620 Praveen Dougal, will summarize recent business highlights before we move to our question 00:01:07.620 -- 00:01:10.060 and answer session. 00:01:10.100 -- 00:01:15.320 Joining Dr. Dougal for the Q&A portion of the call will be Donald Notman, Chief 00:01:15.320 -- 00:01:20.420 Financial Officer and Chief Operating Officer, Sanjay Nayak, Chief Strategy 00:01:20.420 -- 00:01:25.380 Officer, and Steve Myers, Chief Commercial Of...